Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was founded in 2009 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: kintara.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2022 | $6.00 → $3.00 | Buy | HC Wainwright & Co. |
| 9/30/2021 | $7.00 → $5.00 | Buy | Aegis Capital |
| 9/28/2021 | $6.00 | Buy | HC Wainwright & Co. |
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 16, 2024. Kintara announced today that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 18, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger
SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that its Board of Directors (the "Board") has approved a reverse stock split of Kintara's common stock at a ratio of 1-for-35. Kintara's common stock is expected to begin trading on a post-reverse stock split basis on the Nasdaq Capital Market on October 17, 2024, under the new name TuHURA Biosciences, Inc. and under the new symbol "HURA" following the anticipated closing of the merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"), with a new CUSIP number 898920 103.
SAN DIEGO, Oct. 15, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a correction to the press release previously issued by Kintara on October 14, 2024, regarding a record date for the issuance of the Contingent Value Rights ("CVRs") to stockholders of Kintara pursuant to the definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"). Kintara announced today that the CVRs will not be issued to stockholders of record of Kintara based on a record date of October 17, 2024, but rather will be issued stockholders of record of Kint
SAN DIEGO, Oct. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ:KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced a record date of October 17, 2024 (the "Record Date") for the issuance of Contingent Value Rights ("CVRs") to stockholders of record of Kintara as of the Record Date. As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w
SAN DIEGO, Sept. 20, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it adjourned the Special Meeting of Stockholders (the "Special Meeting") held on September 20, 2024. The Special Meeting will reconvene on October 4, 2024 at 9:00 a.m., Eastern Time at www.viewproxy.com/kintarasm/2024. The Company has determined to adjourn the Special Meeting because the voting threshold has not been reached on Proposals 3 & 5, both submitted to stockholders of record to, respectively, (i) approve an amendment to the Kintara Charter (as defined below) to increase the number
Stockholders must vote by 11:59 p.m. ET on September 19, 2024 for their vote to countA "FOR" vote on Proposals 3 & 5 by holders of a majority of the voting power of Kintara's outstanding shares as of August 14, 2024 is required to allow for completion the proposed merger with TuHURA BiosciencesSAN DIEGO, Sept. 18, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, is reminding stockholders to vote at the upcoming Special Meeting of Stockholders to be held on September 20, 2024 to allow for the completion of its proposed merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHU
SAN DIEGO, Sept. 11, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today provided a corporate and REM-001 clinical study update. Corporate Updates In April 2024, Kintara and TuHURA Biosciences, Inc. ("TuHURA") entered into definitive merger agreement (the "Merger Agreement"), pursuant to which Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, will merge with and into TuHURA, with TuHURA surviving the merger and becoming Kintara's direct, wholly-owned subsidiary (the "Merger").Kintara's existing stockholders will own approximately 5.45% of combined company's common st
Stockholders must vote by 11:59 p.m., Eastern Time, on September 19, 2024, for their vote to countSAN DIEGO, Sept. 9, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara") a biopharmaceutical company focused on the development of new solid tumor cancer therapies, encourages all stockholders to vote at the upcoming Special Meeting of Stockholders (the "Special Meeting") to allow for completion of the proposed merger (the "Merger") with TuHURA Biosciences, Inc. ("TuHURA"). As previously announced, Kintara entered into a definitive agreement (the "Merger Agreement") for an all-stock transaction with TuHURA to form a company combining expertise and resources to advance a risk
30 of a projected 39 patients have been enrolled in the clinical trial to date, including a monotherapy arm with KVA12123 and a combination arm utilizing KVA12123 together with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab) Kineta anticipates the trial to be fully enrolled by the end of 2024 TAMPA, Fla. & SAN DIEGO, August 19, 2024 /PRNewswire/ -- TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that Kinet
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
3 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
4 - Kintara Therapeutics, Inc. (0001498382) (Issuer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
EFFECT - Kintara Therapeutics, Inc. (0001498382) (Filer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
POS AM - Kintara Therapeutics, Inc. (0001498382) (Filer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
10-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
425 - Kintara Therapeutics, Inc. (0001498382) (Subject)
8-K - Kintara Therapeutics, Inc. (0001498382) (Filer)
HC Wainwright & Co. reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $3.00 from $6.00 previously
Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $5.00 from $7.00 previously
HC Wainwright & Co. initiated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $6.00
Aegis Capital reiterated coverage of Kintara Therapeutics with a rating of Buy and set a new price target of $7.00 from $6.00 previously
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Tamara A. Seymour to the Company's Board of Directors replacing John Liatos, who will continue in his role as Kintara's Senior Vice President of Business Development. "We are delighted to welcome Tamara to the Board of Directors as she brings exceptional healthcare sector experience as an accomplished financial and operational executive," comm
New York, March 03, 2021 (GLOBE NEWSWIRE) -- - Medexus Pharmaceuticals Inc (CVE:MDP) shares climb as Canaccord Genuity upgrades rating to Buy from Hold following fiscal 3Q results click here - BioPorto A/S (CPH:BIOPOR) expects to complete its clinical study and submit a De Novo application to the US FDA for pediatric use of its NGAL kidney test this summer click here - EVmo Inc (OTCMKTS:YAYO) closes its controlling interest sale to Acuitas Group Holdings click here - Mountain Valley MD Holdings Inc (CSE:MVMD) (OTCQB:MVMDF) brings on Camargo Pharmaceutical Services to boost US FDA approval for Ivectsol click here - Alpine 4 Technologies Ltd (OTCQB:ALPP) appoi
SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debilitating oncology indication," commented Saiid Zarrabian, Kintara's Chief Executive Officer. "We look forward to working closely with Dr. La
SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)
SC 13G - Kintara Therapeutics, Inc. (0001498382) (Subject)
SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)
SC 13G/A - Kintara Therapeutics, Inc. (0001498382) (Subject)
SAN DIEGO, Oct. 8, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal fourth quarter ended June 30, 2024, and provided a corporate update. Recent Corporate Developments As previously disclosed, in April 2024 Kintara entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, w
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments. Recent Corporate Developments Announced that Kintara had entered into a definitive merger agreement (the "Merger Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, and Kayak Mergeco, Inc., Kintara's wholly-owned subsidiary, whereby Kayak Merge
TuHURA is planning to advance a single Phase 3 trial for IFx-2.0 personalized cancer vaccine as adjunctive therapy with Keytruda® in first-line therapy for advanced Merkel cell carcinoma in 2H 2024 under FDA's accelerated approval pathway$31 million subscribed financing by TuHURA in connection with the merger agreement expected to provide cash runway into late 2025TuHURA's first-in-class bifunctional Antibody Drug Conjugates (ADCs) represents potential upside partnering opportunitiesCompanies are to hold a joint conference call and webcast today, Wednesday, April 3 at 8:30 AM ETSAN DIEGO and TAMPA, Fla., April 3, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara"), a bi
SAN DIEGO, Feb. 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2023, and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced the initiation of an open label 15-patient study in cutaneous metastatic breast cancer (CMBC) patients which is evaluating REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent, and is designed to test the 0.8 mg dose as well as optimize the study design in advance of a Phase 3 trial initiation. The primary e
SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that preliminary topline results from the Glioblastoma Adaptive Global Innovative Learning Environment (GBM AGILE) study showed that VAL-083 did not perform better than the current standards of care in glioblastoma. These topline results included preliminary safety data for VAL-083 that was similar to that of the current standards of
SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the clinical development of REM-001, a second-generation photodynamic therapy (PDT) photosensitizer agent for the
SAN DIEGO, May 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Case study data from two abstracts was presented by MD Anderson Cancer Center from the VAL-083 expanded access program at the American Association for Cancer Research (AACR) Annual Meeting (April):RELA fusion-positive ependymoma and diffuse midline glioma treated with VAL-083 under expanded access - case reports. The abstract described two patient
SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal second quarter ended December 31, 2022 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Announced that Kintara had received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for VAL-083 for the treatment of diffuse intrinsic pontine glioma, a rare and highly aggressive childhood brain cancer (December).Received formal notice from The Nasdaq Stock Market LLC stating that Kintara had regained compliance with
SAN DIEGO, Nov. 9, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ:KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal first quarter ended September 30, 2022 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Paused the REM-001 program in Cutaneous Metastatic Breast Cancer (CMBC) to conserve cash which will be used to support the funding of the Company's ongoing international registrational study for VAL-083 in glioblastoma (GBM). By pausing the REM-001 program, the Company expects to save approximately $3.0 million through 2023 (Octo
SAN DIEGO, Sept. 27, 2022 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2022 and provided a corporate update. CORPORATE HIGHLIGHTS AND RECENT DEVELOPMENTS Announced that three posters were accepted for data presentation at the 2022 Society for Neuro-Oncology ("SNO") Annual Meeting. The 2022 SNO Annual Meeting will be held from November 16 through November 20, 2022 in Tampa, Florida (September).Received a Study May Proceed letter from the United States Food and Drug Administration ("FDA") to
KVA12123 is a rationally targeted, anti-VISTA antibody checkpoint inhibitor to reverse VISTA immune suppression and remodel the tumor microenvironment (TME) to overcome acquired resistance to immunotherapies KVA12123 is currently in a Phase 1/Phase 2 clinical study as a monotherapy and in combination with Merck's anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors To date, KVA12123 has demonstrated a favorable clinical safety and tolerability profile observed with no dose limiting toxicities and no evidence of Cytokine Release Syndrome (CRS) associated toxicities at doses examined Concurrent $5 million investment from existing TuHURA shareholder preserves
Gainers DermTech (NASDAQ:DMTK) stock rose 56.6% to $0.18 during Friday's pre-market session. The market value of their outstanding shares is at $6.4 million. Sarepta Therapeutics (NASDAQ:SRPT) shares rose 39.26% to $171.99. The market value of their outstanding shares is at $16.2 billion. Kintara Therapeutics (NASDAQ:KTRA) shares increased by 17.78% to $0.32. The market value of their outstanding shares is at $17.9 million. Solid Biosciences (NASDAQ:SLDB) stock moved upwards by 17.3% to $7.39. The market value of their outstanding shares is at $283.6 million. ASLAN Pharma (NASDAQ:ASLN) stock rose 14.06% to $0.36. The market value of their outstanding shares is at $8.2 million. Alaunos
Gainers Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 68.1% to $1.0 during Thursday's after-market session. The market value of their outstanding shares is at $13.3 million. Kintara Therapeutics (NASDAQ:KTRA) shares moved upwards by 15.67% to $0.32. The market value of their outstanding shares is at $17.5 million. Talphera (NASDAQ:TLPH) shares rose 12.64% to $0.92. The market value of their outstanding shares is at $15.6 million. Helius Medical Tech (NASDAQ:HSDT) shares moved upwards by 10.11% to $1.06. The market value of their outstanding shares is at $3.1 million. Clover Health Investments (NASDAQ:CLOV) stock rose 9.72% to $1.13. The company's market cap stands at $561.0 mil
Shares of Quantum Corporation (NASDAQ:QMCO) fell sharply during Tuesday's session after the company reported worse-than-expected FY24 financial results and issued FY25 guidance below estimates. Quantum shares dipped 44.5% to $0.43 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers Reliance Global Group, Inc. (NASDAQ:RELI) shares jumped 350% to $1.00 after the company issued an update on the pending acquisition of Spetner Associates. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 166% to $0.3930 after jumping 30% on Monday. Actelis Networks, Inc. (NASDAQ:ASNS) climbed 80.9% to $2.08 after the company announced a partnership with Carahsoft Tech
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 50.0% to $1.12 during Tuesday's regular session. The company's market cap stands at $31.7 million. Sonoma Pharmaceuticals (NASDAQ:SNOA) shares increased by 27.95% to $0.22. The company's market cap stands at $3.3 million. The company's, Q4 earnings came out yesterday. Vaxart (NASDAQ:VXRT) shares moved upwards by 27.83% to $0.67. The market value of their outstanding shares is at $118.6 million. Silk Road Medical (NASDAQ:SILK) shares moved upwards by 23.92% to $26.86. The company's market cap stands at $1.0 billion. Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.1% to $0.21. The company's market cap stands at $11.6 million. Atri
Shares of Chegg, Inc. (NYSE:CHGG) rose sharply in today's pre-market trading after the company announced a restructuring plan and new vision for growth. The restructuring plan will include a 23% headcount reduction, a refocus on students with a comprehensive course load and dedication of more resources to its international program. Chegg shares jumped 20.7% to $3.15 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) rose 112.2% to $2.44 in pre-market trading after the company announced a partnership with Carahsoft Technology Corp. NLS Pharmaceutics AG (NASDAQ:NLSP) shares rose 62.8% to $0
Gainers Vaxart (NASDAQ:VXRT) shares increased by 146.7% to $1.85 during Thursday's after-market session. The market value of their outstanding shares is at $327.1 million. Venus Concept (NASDAQ:VERO) stock rose 10.32% to $0.95. The company's market cap stands at $6.0 million. Vincerx Pharma (NASDAQ:VINC) stock moved upwards by 5.99% to $0.73. The market value of their outstanding shares is at $21.5 million. Kintara Therapeutics (NASDAQ:KTRA) shares rose 5.82% to $0.2. The company's market cap stands at $10.9 million. Beyond Air (NASDAQ:XAIR) shares moved upwards by 5.64% to $1.31. The company's market cap stands at $60.1 million. Soligenix (NASDAQ:SNGX) stock rose 5.42% to $4.38. The m
Gainers Concord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANNX) shares increased by 32.96% to $6.09. The company's market cap stands at $562.7 million. Olema Pharmaceuticals (NASDAQ:OLMA) stock moved upwards by 26.7% to $14.9. The company's market cap stands at $833.4 million. Pasithea Therapeutics (NASDAQ:KTTA) shares moved upwards by 22.59% to $7.0. The market value of their outstanding shares is at $7.3 million. Fresh2 Group (NASDAQ:FRES) stock moved upwards by 21.12% to $0.43. The company's market cap stands at $10.5 million. I-MAB (NASDAQ:IMAB
TuHURA's lead candidate, IFx-2.0, was safe and well tolerated at once weekly dosing for 3 weeksEighty percent (80%) of ICI naïve patients with advanced MCC who failed to respond to pembrolizumab or avelumab therapy achieved a durable Complete Response (CR), pathologic CR or Partial Response (PR) following IFx-2.0 therapy and rechallenge with an anti-PD(L)-1 checkpoint inhibitorData presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting